Stable COPD — maintenance (GOLD ABE groups; inhaler therapy)
stable-copd-maintenance · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Long-term pharmacological and non-pharmacological management of stable COPD — distinct from the acute COPD exacerbation entry. GOLD uses the ABE assessment (symptoms by mMRC/CAT + exacerbation history) to guide initial inhaler choice, with blood eosinophils informing ICS use. Goal: reduce symptoms and future exacerbation risk, preserve function.
Red flags
- Frequent/severe exacerbations despite optimal inhaled therapy
- Progressive breathlessness or falling FEV1
- Resting hypoxaemia (consider LTOT assessment)
- Weight loss / haemoptysis / new focal signs — exclude malignancy
- Signs of cor pulmonale / right heart failure
- Overlap with sleep-disordered breathing (daytime hypercapnia)
Assessment
Differential diagnosis
- Asthma / asthma-COPD overlap
- Bronchiectasis
- Heart failure
- Chronic pulmonary thromboembolic disease
- Interstitial lung disease
- Lung cancer
- Alpha-1 antitrypsin deficiency (consider if young/non-smoker/basal emphysema)
Investigations
- Post-bronchodilator spirometry (FEV1/FVC <0.70) — required to diagnose; GOLD grades 1-4 by FEV1% predicted
- Symptom burden: mMRC dyspnoea scale and/or CAT score
- Exacerbation history over past 12 months (number, hospitalisations) -> GOLD group A, B or E
- Blood eosinophil count (guides ICS)
- CXR; consider CT if suspicion of bronchiectasis/malignancy/emphysema distribution
- Alpha-1 antitrypsin level once in all COPD (esp. young/non-smoker)
- Pulse oximetry +/- ABG; assess for chronic hypoxaemia (consider LTOT if PaO2 <=7.3 kPa, or <=8.0 with cor pulmonale/polycythaemia)
- Screen comorbidities: cardiovascular disease, osteoporosis, depression, anxiety; BMI/nutrition
Management
- Confirm diagnosis with post-bronchodilator spirometry — do not treat 'COPD' without obstruction
- Classify by GOLD group: A (low symptoms, 0-1 non-hospitalised exacerbation), B (more symptoms, 0-1 exacerbation), E (>=2 moderate or >=1 hospitalised exacerbation/yr)
- Group A: one long-acting bronchodilator (LABA or LAMA)
- Group B: LABA + LAMA dual bronchodilator (single inhaler preferred)
- Group E: LABA + LAMA; add ICS (triple therapy) if blood eosinophils >=300 cells/microlitre
- Non-pharmacological bundle is central: smoking cessation (most important), pulmonary rehabilitation, influenza + pneumococcal + COVID vaccination
- Follow-up review of symptoms and exacerbations; escalate/de-escalate using the eosinophil-guided pathway
- Assess LTOT, inhaler technique, and self-management/action plan at each review
- Consider roflumilast or azithromycin in selected frequent exacerbators on triple therapy (specialist); lung volume reduction / transplant in advanced disease
Drugs & doses
Tiotropium 18 micrograms inhalation powder once daily (or 5 micrograms Respimat OD) — LAMA
Indacaterol/glycopyrronium or umeclidinium/vilanterol or similar LABA/LAMA once daily (single-inhaler dual bronchodilator) [verify local product]
Fluticasone furoate/umeclidinium/vilanterol (or budesonide/glycopyrronium/formoterol) once/twice daily — single-inhaler triple therapy where ICS indicated [verify local product]
Salbutamol 100-200 micrograms inhaled PRN as short-acting reliever
Roflumilast 500 micrograms PO once daily — selected severe COPD with chronic bronchitis and frequent exacerbations (specialist)
Azithromycin 250-500 mg PO three times weekly — long-term for frequent exacerbators (exclude NTM, baseline ECG/QTc; specialist) [verify local dose]
Disposition
Primary care / respiratory outpatient. Refer for pulmonary rehabilitation, LTOT assessment, or specialist review if frequent exacerbations, severe airflow limitation, suspected overlap, or candidacy for advanced therapies.
Complications & pitfalls
- Recurrent exacerbations and hospitalisation
- Chronic respiratory failure, cor pulmonale
- Pneumonia (higher risk with ICS)
- Secondary polycythaemia
- Pneumothorax (bullous disease)
- Osteoporosis, cachexia, depression, cardiovascular disease
Exam pearls
- GOLD 2024/2025: initial therapy by ABE group — A single bronchodilator, B and E start LABA+LAMA; add ICS in group E when eosinophils >=300 (GOLD Report).
- Avoid ICS monotherapy in COPD; ICS raises pneumonia risk — favour it in eosinophilic frequent-exacerbator phenotype, avoid with eos <100 or repeated pneumonia.
- Smoking cessation and pulmonary rehabilitation are the only interventions (with LTOT and lung volume reduction in selected patients) shown to alter the natural history/mortality.
- Note: the 2026 GOLD report lowered the threshold for group E to any >=1 moderate/severe exacerbation per year — verify against the current report in use locally.
- Always check inhaler technique and adherence before escalating.
- Triple therapy (LABA/LAMA/ICS) reduces exacerbations and mortality vs dual in the eosinophilic frequent-exacerbator group.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.